BKBrad Kolls

Brad Kolls

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brad Kolls has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of a Handheld Near-Infrared Light Device in Detecting Intracranial Hematomas in Mbarara, Uganda

    by Yuh Yiing Liow, Alvan-Emeka K. Ukachukwu, Edwin S. Iversen, Yesel Trillo Ordonez, Robert Gramer, Nathan A. Shlobin, Josephine N. Najjuma, Anthony T. Fuller, Michael M. Haglund, David Kitya, et al.

    BACKGROUND AND OBJECTIVES: Traumatic brain injury (TBI) is one of the leading causes of mortality worldwide. Low- and middle-income countries have limited access to computed tomography scans (CT), which are essential in TBI care. The Infrascanner 2000™ is a low-cost, portable near-infrared device that could be used as a triage device to prioritize the use of a confirmatory CT scan in detecting post-traumatic intracranial bleeds. The aim of this observational study (NCT04505293) was to determine the diagnostic performance of the Infrascanner 2000™ in comparison with CT in TBI patients in Mbarara Regional Referral Hospital (MRRH), Uganda. METHODS: Patients with suspected head trauma in MRRH who received a head CT were included. They were scanned with the Infrascanner™ within 30 minutes after their CT. The patients' demographics, clinical characteristics, and device diagnostic performance were recorded. Data from our previous study at Duke University Hospital was combined with this study data to determine factors that could account for differences found in device performance. RESULTS: Of the 384 patients in MRRH, 180 had intracranial hematomas. The device had a sensitivity of 88.9% and a specificity of 37.7%. This high sensitivity applied to all tested hemorrhage locations and various hemorrhage types. The combined study had a sensitivity of 87.4% and a specificity of 75.1%. Dark skin color was found to be a factor resulting in the low specificity observed. CONCLUSION: Our data demonstrate that the Infrascanner 2000™ performs well at detecting intracranial hematomas with high sensitivity and low false negatives. The decrease in specificity may be related to darker skin color; however, additional studies using updated versions of the device are needed.


  • Usability, Face Validity, Feasibility, and Reliability of 3 Neurocritical Care Electronic Clinical Quality Measures

    by Abhijit Vijay Lele, Emma Pendl-Robinson, Samuel Simon, Keith Dombrowski, Bradley J. Kolls, Matthew W. Luedke, Christine T. Fong, Erin Lee, Paul M. Vespa, Sarah Livesay, et al.

    The field of neurology lacks neurocritical care (NCC) quality measures because of the complexity of neurologic disorders and challenges in data collection, hindering efforts to assess care quality and improve patient outcomes. This study examined the feasibility, usability, and scientific acceptability of 3 new facility-level neurology electronic clinical quality measures (eCQMs): (1) adult patients with generalized convulsive status epilepticus (GCSE) treated with benzodiazepine within 20 minutes of arrival to the emergency department, (2) dexamethasone administration before or within an hour of the first dose of antibiotics in patients with acute bacterial meningitis (BM), and (3) immunomodulatory therapy [plasma exchange or IV immunoglobulin] for myasthenic crisis (MG). We evaluated the feasibility, usability, face validity, and reliability of the 3 eCQMs across 3 sites in the United States using a combination of qualitative and quantitative methodologies. The feasibility of reporting was evaluated by the percentage of data elements that do not require manual patient record review. Face validity was determined through semistructured clinician interviews and web survey, and usability was assessed through clinician interviews. Signal-to-noise reliability was calculated based on the testing data obtained from 3 hospitals. The total number of denominator-eligible patients in the sample was 86 (GCSE), 88 (BM), and 193 (MG). The mean measure rates were as follows: GCSE, 12.3% (11.3%-13.3%); BM, 23.3% (10.8%-35.7%); and MG, 64.2% (46.2%-81.4%). All 3 eCQMs had high face validity (GCSE: 90%, BM: 90%, MG: 94%). The measures had high reliability: GCSE, 0.890 (0.816-0.963); BM, 0.817 (0.669-0.964); and MG, 0.958 (0.948-0.969). We found high feasibility for MG; however, BM and GCSE had feasibility concerns for several key data elements. Clinicians supported the measures' potential to improve care but expressed several usability concerns. The eCQMs showed potential for being used for quality improvement. However, significant barriers to feasibility include inconsistent recording of diagnosis and procedure codes in electronic health records and underestimation of denominator and/or numerator cases, which hinder reporting in Centers for Medicare & Medicaid Services quality improvement programs. Continued refinement of the eCQM specifications is required before they can be implemented to enhance their impact on NCC quality.


  • Population‐based prevalence of epilepsy in Uganda: A nationwide cross‐sectional survey

    by Angelina Kakooza‐Mwesige, Anthony T. Fuller, Paula N. Njeru, Fredrick E. Makumbi, Christine Muhumuza, Noeline Nakasujja, Mark Kaddumukasa, Martin N. Kaddumukasa, Juliet Nakku, Michael M. Haglund, et al.

    Objective: Establishing the prevalence of epilepsy in Uganda is crucial to inform interventions and public policy. We conducted a nationwide survey to determine epilepsy prevalence. Methods: From January 2019 to July 2022, a door‐to‐door survey was conducted across all four regions of Uganda, targeting a nationally representative sample of households. Trained field teams identified and interviewed heads of households to obtain demographic information, and three household members were randomly selected for epilepsy screening. A two‐part survey, adapted from a validated standardized epilepsy questionnaire in low‐ and middle‐income countries, was used for screening. To ensure the accuracy of the prevalence estimates, a subset of screened individuals underwent clinical validation by a qualified neurologist. Epilepsy was defined per the International League Against Epilepsy (ILAE) criteria. We employed Monte Carlo simulation to extrapolate prevalence estimates. Results: We identified and screened 35 055 participants (53.5% female). The ages ranged from 1 month to 108 years, with a mean age of 20.7 years. The overall crude epilepsy prevalence was estimated at 16.9 per 1000 persons, with an age‐ and sex‐adjusted prevalence rate of 17.8 per 1000. The differences in sex‐specific prevalence rates were not statistically significant. The highest age‐specific prevalence rate of 25.0 per 1000 occurred in the 20‐ to 39 ‐year age group. There was a substantial variation in epilepsy prevalence across the various regions, with the highest prevalence recorded in the eastern region and the lowest in the northern region. Significance: Our study underscores the high epilepsy burden in Uganda, particularly among adults, and reveals age, gender, and geographical variation likely arising from disparities in the underlying determinants. Identification of these factors is crucial for addressing treatment gaps and reducing epilepsy prevalence.


  • Telestroke consultant use in acute stroke care: Evidence for best practices from the IMPROVE stroke care program

    by Brad J Kolls, Edwin Iversen, Lisa Monk, Shreyansh Shah, Carmelo Graffagnino, Matthew E Ehrlich

    Background: Evolving stroke care demands careful screening of stroke patients to ensure the right care is administered to the right patients in a timely manner. Telestroke has been increasingly utilized to improve access to stroke specialists to make these assessments. Here we explore the care processes at these telestroke site to determine if an optimal care process can be determined. Methods: This is a post-hoc analysis of data collected as part a larger quality improvement program, the IMPROVE stroke care program. We rank ordered and normalized the DTN times from encounters that used telestroke services to range between 0 and 1. We used linear mixed models to assess the acute stroke care process steps most associated with improvement in thrombolytic administration times. Results: The dataset consisted of 21,456 acute stroke code assessments, of which 8356 (80.6%) were conducted via telestroke (TS) services. Of these TS events, 7088 (84.8%) were conducted at sites that used TS for >85% of all events. Compared to private vehicle, EMS arrival is associated with 4% improvement in DTN ranks, though when paired with prehospital notification, DTN ranks significantly improve by 25%. Key process steps associated with shorter DTN times included calling a code stroke quickly upon arrival and notifying the telestroke consultant prior to obtaining the initial CT scan. Discussion: Working with local EMS to provide prehospital notification along with rapid code stroke activation and consultant notification prior to CT were identified as best practices for providing timely acute stroke care using telestroke providers.


  • Improve time to anti-coagulation reversal for hemorrhagic strokes

    by Braydon Dymm, Carmelo Graffagnino, Gabriel Torrealba Acosta, Matthew E Ehrlich, Lisa Monk, Shreyansh Shah, Edwin Iversen, Brad J Kolls


  • Open Access

    IMPROVE Time to Anti-Coagulation Reversal for Hemorrhagic Strokes

    by Braydon Dymm, Carmelo Graffagnino, Gabriel Torrealba Acosta, Matthew Ehrlich, Lisa Monk, Shreyansh Shah, Edwin Iversen, Brad Kolls

    Background Oral anticoagulation (OAC) is a risk factor for intracerebral hemorrhage (ICH) which is an important source of disability and mortality. OAC-associated ICH (OAC-ICH) patients have worse outcomes as compared to ICH patients not on OAC, likely because of the associated larger stroke volumes, higher propensity to intraventricular hemorrhage, and a higher risk of rebleeding. Although current guidelines recommend that OAC should be reversed quickly, many health care systems have not developed a process for optimizing that aspect of care. Methods Through the IMPROVE Stroke Care Consortium, a group of nine Hub hospitals and their 57 regional community hospitals, a systems of care improvement project was implemented. Performance reviews identified best practices which were disseminated throughout all centers. We compared the median door-to-reversal (DTR) time before and after an institutional campaign to speed the process with a target time of 60 minutes. Results Over two years of the study, there were 6,699 ischemic strokes, 152 subarachnoid hemorrhages, and 889 intracerebral hemorrhages. During that time, 36 hemorrhagic stroke patients received reversal agents emergently. The overall baseline median DTR time was 123 minutes (IQR 99, 361 minutes). By the end of the program, the median DTR time had trended down to 84 minutes (IQR 58.5, 151 minutes) which is a 31.7% reduction of DTR from baseline, though times remained somewhat variable (p = 0.08). Conclusions Utilizing an integrated stroke systems of care approach, we were able to reduce DTR times for patients presenting with acute ICH and concurrent use of anticoagulants despite lack of definitive guidelines around targets for reversal times or operational guidance on protocols and agents.

  • Open Access

    Experience with a hybrid recruitment approach of patient-facing web portal screening and subsequent phone and medical record review for a neurosurgical intervention trial for chronic ischemic stroke disability (PISCES III)

    by Brad J. Kolls, Keith W. Muir, Sean I. Savitz, Lawrence R. Wechsler, Julie G. Pilitsis, Scott Rahimi, Richard L. Beckman, Vincent Holmes, Peng R. Chen, David S. Albers, et al.

    Background: Recruitment of participants is the greatest risk to completion of most clinical trials, with 20–40% of trials failing to reach the targeted enrollment. This is particularly true of trials of central nervous system (CNS) therapies such as intervention for chronic stroke. The PISCES III trial was an invasive trial of stereotactically guided intracerebral injection of CTX0E03, a fetal derived neural stem cell line, in patients with chronic disability due to ischemic stroke. We report on the experience using a novel hybrid recruitment approach of a patient-facing portal to self-identify and perform an initial screen for general trial eligibility (tier 1), followed by phone screening and medical records review (tier 2) prior to a final in-person visit to confirm eligibility and consent. Methods: Two tiers of screening were established: an initial screen of general eligibility using a patient-facing web portal (tier 1), followed by a more detailed screen that included phone survey and medical record review (tier 2). If potential participants passed the tier 2 screen, they were referred directly to visit 1 at a study site, where final in-person screening and consent were performed. Rates of screening were tracked during the period of trial recruitment and sources of referrals were noted. Results: The approach to screening and recruitment resulted in 6125 tier 1 screens, leading to 1121 referrals to tier 2. The tier 2 screening resulted in 224 medical record requests and identification of 86 qualifying participants for referral to sites. The study attained a viable recruitment rate of 6 enrolled per month prior to being disrupted by COVID 19. Conclusions: A tiered approach to eligibility screening using a hybrid of web-based portals to self-identify and screen for general eligibility followed by a more detailed phone and medical record review allowed the study to use fewer sites and reduce cost. Despite the difficult and narrow population of patients suffering moderate chronic disability from stroke, this strategy produced a viable recruitment rate for this invasive study of intracranially injected neural stem cells. Trial registration: ClinicalTrials.gov Identifier: NCT03629275


  • Optimization of a translational murine model of closed-head traumatic brain injury

    by Brian E. Mace, Eric Lassiter, Evangeline Kamalini Arulraja, Eduardo Chaparro, Viviana Cantillana, Rupali Gupta, Timothy D. Faw, Daniel T. Laskowitz, Brad J Kolls

    Traumatic brain injury (TBI) from closed-head trauma is a leading cause of disability, with limited effective interventions. Many TBI models impact brain parenchyma directly, and are limited by the fact that these forces do not recapitulate clinically relevant closed head injury. However, applying clinically relevant injury mechanics to the intact skull may lead to variability and as a result, preclinical modeling TBI remains a challenge. Current models often do not explore sex differences in TBI, which is critically important for translation to clinical practice. We systematically investigated sources of variability in a murine model of closed-head TBI and developed a framework to reduce variability across severity and sex. We manipulated pressure, dwell time, and displacement to determine effects on motor coordination, spatial learning, and neuronal damage in 10-week-old male and female mice. Increasing pressure beyond 70 psi had a ceiling effect on cellular and behavioral outcomes, while manipulating dwell time only affected behavioral performance. Increasing displacement precisely graded injury severity in both sexes across all outcomes. Physical signs of trauma occurred more frequently at higher displacements. Stratifying severity based on day-1 rotarod performance retained histological relationships and separated both sexes into injury severity cohorts with distinct patterns of behavioral recovery. Utilizing this stratification strategy, within-group rotarod variability over 6 days post-injury was reduced by 50%. These results have important implications for translational research in TBI and provide a framework for using this clinically relevant translational injury model in both male and female mice.


  • Open Access

    Regionalization of stroke systems of care in the stroke belt states: The IMPROVE stroke care quality improvement program

    by Brad J. Kolls, Matthew E. Ehrlich, Lisa Monk, Shreyansh Shah, Mayme Roettig, Edwin Iversen, James G. Jollis, Christopher B. Granger, Carmelo Graffagnino


  • Open Access

    Methodological considerations in PISCES 3: a randomized, placebo-controlled study of intracerebral stem cells in subjects with disability following an ischemic stroke

    by Daniel T. Laskowitz, Keith W. Muir, Sean I. Savitz, Lawrence R. Wechsler, Julie G. Pilitsis, Scott Y. Rahimi, Richard L. Beckman, Vincent Holmes, Peng R. Chen, Laura Juel, et al.

    Background and hypothesis: At present, there are no medical interventions proven to improve functional recovery in patients with subacute stroke. We hypothesize that the intraparenchymal administration of CTX0E03, a conditionally immortalized neural stem cell line, linked with a standardized rehabilitation therapy regimen for the upper limb, would improve functional outcomes in patients 6–12 months after an index ischemic stroke.Study design: PISCES III was designed as a multicenter prospective, sham-controlled, outcome-blinded randomized clinical trial. Eligibility required a qualifying ischemic stroke 6–12 months prior to surgical intervention. Patients must be between 35 and 75 years of age and have residual moderate or moderately severe disability (mRS 3 or 4), with the preservation of some residual upper limb movement. All patients received a standardized regimen of home physical therapy following the intervention.Study outcomes: The primary outcome measure is improvement in the modified Rankin Scale (mRS) of disability at 6 months post treatment. Secondary outcomes include assessment of activities of daily living (Barthel Index), functional mobility (Timed Up and Go; Fugl Meyer Assessment), neurological impairment (NIHSS), upper limb function (Chedoke Arm and Hand Inventory), as well as patient related quality of life and global rating scales.Discussion: PISCES III was designed as a randomized trial directly comparing the effects of intraparenchymal injection of a conditional stem cell line vs. sham procedure in patients with subacute stroke. This is one of the first studies of this type to include a standardized minimum rehabilitation protocol. As there are a limited number of studies evaluating invasive stem cell administration in the chronic setting of CNS injury, study design considerations are discussed.Clinical Trial Registration: https://clinicaltrials.gov/, identifier NCT03629275.